These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27960087)

  • 41. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
    Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
    Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. β-lapachone suppresses tumour progression by inhibiting epithelial-to-mesenchymal transition in NQO1-positive breast cancers.
    Yang Y; Zhou X; Xu M; Piao J; Zhang Y; Lin Z; Chen L
    Sci Rep; 2017 Jun; 7(1):2681. PubMed ID: 28578385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer.
    Liu F; Yu G; Wang G; Liu H; Wu X; Wang Q; Liu M; Liao K; Wu M; Cheng X; Hao H
    PLoS One; 2012; 7(7):e42138. PubMed ID: 22848731
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair.
    Bentle MS; Reinicke KE; Bey EA; Spitz DR; Boothman DA
    J Biol Chem; 2006 Nov; 281(44):33684-96. PubMed ID: 16920718
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
    Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.
    Hastak K; Bhutra S; Parry R; Ford JM
    Oncotarget; 2017 Apr; 8(16):26344-26355. PubMed ID: 28412751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer.
    Qadir MI; Iqbal MS; Khan R
    Curr Cancer Drug Targets; 2022; 22(7):537-540. PubMed ID: 35490325
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting Base Excision Repair in Cancer: NQO1-Bioactivatable Drugs Improve Tumor Selectivity and Reduce Treatment Toxicity Through Radiosensitization of Human Cancer.
    Starcher CL; Pay SL; Singh N; Yeh IJ; Bhandare SB; Su X; Huang X; Bey EA; Motea EA; Boothman DA
    Front Oncol; 2020; 10():1575. PubMed ID: 32974194
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
    Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
    Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells.
    Ryu H; Choi HK; Kim HJ; Kim AY; Song JY; Hwang SG; Kim JS; Kim DU; Kim EH; Kim J; Ahn J
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554189
    [TBL] [Abstract][Full Text] [Related]  

  • 51. β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers.
    Tumbath S; Jiang L; Li X; Zhang T; Zahid KR; Zhao Y; Zhou H; Yin Z; Lu T; Jiang S; Chen Y; Chen X; Fu YX; Huang X
    Oncoimmunology; 2024; 13(1):2363000. PubMed ID: 38846085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3.
    Planchon SM; Pink JJ; Tagliarino C; Bornmann WG; Varnes ME; Boothman DA
    Exp Cell Res; 2001 Jul; 267(1):95-106. PubMed ID: 11412042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phytochemical naphtho[1,2-b] furan-4,5‑dione induced topoisomerase II-mediated DNA damage response in human non-small-cell lung cancer.
    Chien CM; Yang JC; Wu PH; Wu CY; Chen GY; Wu YC; Chou CK; Tseng CH; Chen YL; Wang LF; Chiu CC
    Phytomedicine; 2019 Feb; 54():109-119. PubMed ID: 30668360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
    Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer.
    Wang Y; Zuo M; Jin H; Lai M; Luo J; Cheng Z
    J Recept Signal Transduct Res; 2021 Jun; 41(3):304-311. PubMed ID: 32814472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC.
    Madajewski B; Boatman MA; Chakrabarti G; Boothman DA; Bey EA
    Mol Cancer Res; 2016 Jan; 14(1):14-25. PubMed ID: 26553038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 60. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
    McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
    Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.